Search results
Showing 1 to 9 of 9 results for formoterol
Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.
View recommendations for TA138Show all sections
Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in children under 12.
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)
This evidence summary has been updated and replaced by NICE guideline 115.
Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)
This evidence summary has been updated and replaced by NICE guideline 115.
Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)
This evidence summary has been updated and replaced by NICE guideline NG80.
Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)
This evidence summary has been updated and replaced by NICE guideline 115.
Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)
This evidence summary has been updated and replaced by NICE guideline NG80.
Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)
This evidence summary has been updated and replaced by NICE guideline NG80.